| Literature DB >> 30530626 |
Saidatul N Buang1, Safurah Ja'afar2, Indra Pathmanathan3, Victoria Saint4.
Abstract
Entities:
Mesh:
Substances:
Year: 2018 PMID: 30530626 PMCID: PMC6282734 DOI: 10.1136/bmj.k4602
Source DB: PubMed Journal: BMJ ISSN: 0959-8138
Public expenditure on health and education in Malaysia and other countries (% of gross domestic product)
| Country | Health | Education | |||
|---|---|---|---|---|---|
| 2000 | 2015 | 2000 | 2012 | ||
| Malaysia | 2.43 | 4.00 | 6.00 | 5.10 | |
| Australia | 7.60 | 9.45 | 4.90 | 5.10 | |
| Thailand | 3.19 | 3.77 | 5.40 | 5.80 | |
| Indonesia | 2.01 | 3.35 | 2.90 | 2.80 | |
| Cambodia | 6.40 | 5.98 | 1.70 | 2.60 | |
Collaborative activities that led to the national policy on HPV immunisation
| Key stakeholders | Collaborative activities | Outputs |
|---|---|---|
| Academics in universities and institutions (problem stream) | Generated evidence | • Cost of vaccine was estimated at about £260 (MYR1300; $378) per person* |
| Pharmaceutical companies (problem stream) | Supported academics to produce evidence | Local cost effectiveness studies of bivalent and quadrivalent vaccines and scaling up the smear test programme |
| Supported medical associations to conduct seminars | Presumed to have increased awareness and appreciation of the benefits of HPV immunisation | |
| Participated in meetings with key decision makers in the Ministry of Health | ||
| Ministry of health (policy stream) | Convened a multidisciplinary group of public and private sector specialists to provide policy advice | Reviewed (a) HPV immunisation programmes in Australia, United Kingdom, and other countries, and (b) evidence on the disease burden of cervical cancer in Malaysia and cost effectiveness of immunisation |
| Stakeholder consultations | Used this evidence to gather support from ministries of finance, education, women, and family development, and professional medical associations | |
| Public (civil society, mass media) and politicians (political stream | Advocacy activities on cancer in women, and human interest stories on the illness and death from cancer of the prime minister’s wife | Heightened public and political visibility of and support for cancer prevention |
| Malaysian cabinet chaired by the recently bereaved prime minister (window of opportunity where the three streams converged) | Consideration of a cabinet paper from the Ministry of Health to include HPV vaccination in the national childhood immunisation programme | Approval of the policy and budget |
Fig 1Timeline of the programme on HPV immunisation in Malaysia
Fig 2Number and percentage of 13 year old girls vaccinated through the programme on HPV immunisation, 2010-16
Fig 3Mechanisms for collaboration between the ministries of health and education for implementation of the programme on HPV immunisation in Malaysia
Collaborations in planning and monitoring that helped overcome challenges in implementing the programme on HPV immunisation
| Implementation challenge | Collaborating stakeholders | Contribution of collaboration to overcoming implementation challenges |
|---|---|---|
| Ensure right amount of vaccine is available in the right places at the right time | District education departments | Provided data to 650 school health teams on school locations and enrolments to accurately calculate vaccine requirements |
| School health teams | Validated and supplemented enrolment data through visits to schools not on the register of district education offices | |
| District health officers | Informed national Ministry of Health of suitable locations for additional refrigerators for vaccine storage to be supplied by the pharmaceutical company | |
| National Ministry of Health (school health unit) | Calculated and informed the pharmaceutical company of the sites to supply new refrigerators, the vaccine amounts needed for each of the 640 storage locations nationwide, and the schedule of vaccine requirements based on the vaccination schedule of 0, 1 and 6 month intervals | |
| Pharmaceutical company | Based on data from the Ministry of Health, planned schedule for contractors to deliver the refrigerators to correct sites and the vaccine to the 640 locations according to the schedule for each location | |
| Ensure that immunisation days do not interfere with the school curriculum | District education officers and school heads | Informed school health teams of key dates (eg, examinations, sports days, holidays) in each school’s calendar for form 1 (13 year olds) |
| School health teams and school heads | Planned school visit schedule and informed school heads | |
| Ensure timely informed consent from parents | National Ministry of Health (school health unit) and state and district health teams | Provided educational briefings on HPV immunisation and its benefits to school heads and teachers |
| School health teams and school heads | Agreed on schedules for obtaining signed consent forms and immunisation dates | |
| School heads and teachers | Provided briefings to schoolchildren and parents, and distributed and collected consent forms | |
| Reduce risk of drop outs between first and last dose in the immunisation schedule | School health teams and district health teams | Ensured first dose was planned so that the schedule could be completed in the same academic year, and included this criterion for estimating vaccine supply schedules |
| Ensure integrity of the cold chain | Pharmaceutical company and its outsourced contractors, and health staff at the district level | • Developed web based software |
| Prompt detection of implementation problems | Health care managers (Ministry of Health) at national, state, and district levels and school health teams | • Electronic communication provided data on implementation coverage and adverse events following immunisation daily and then weekly to operations rooms at district, state, and national levels |
Interagency and intra-agency collaboration to monitor and respond to rumours
| Collaborating stakeholders | Structural features | Functional outputs |
|---|---|---|
| • Healthcare managers (Ministry of Health) at national and state levels | • Toll free hotline financed by the pharmaceutical company was installed at Ministry of Health headquarters | • Real time monitoring of rumours and public/consumer concerns |
Fig 6Stakeholders in Malaysia’s programme on HPV immunisation
Characteristics of key collaborations in the programme on HPV immunisation
| Key stakeholders and type of collaboration | Structural features or processes | Functional outputs that supported planning, monitoring, and communication |
|---|---|---|
|
| Vertical collaboration: overlapping national, state, district, and local groups within each sector | Transmission of authority through guidelines and credible materials for briefings and training |
| Real time recognition of problems and identification of possible solutions | ||
| Accountability through progress reporting | ||
| Horizontal collaboration: between the health and education sectors at each level | Clarification and acceptance of roles and responsibilities (eg, that teachers must obtain signed consent forms from parents) | |
| Exchange of local information (eg, that teachers and students are generally aware of cancer but not of HPV; and data on school enrolments and academic calendars to enable planning and health team visit schedules) | ||
| System for monitoring adverse events after immunisation, based on WHO classification | ||
|
| Funding for academic researchers | Local studies on cost effectiveness published in peer reviewed international journals |
| Support for professional medical associations | Educational and promotional activities about the benefits of HPV immunisation | |
| Contractual relationship with the Ministry of Health | Vaccine price: senior Ministry of Health officials negotiated significant price reductions using arguments of economies of scale, long term future commitment to vaccine purchase as part of the regular budget, and the reputation of the Ministry of Health as a good client | |
| Professional and contractual relationship with the Ministry of Health | Complementary provision of additional cold chain equipment, injection consumables, and funding for promotional activities | |
|
| Informal meetings between key people | Fatwa (formal ruling) by an Islamic authority that the use of the HPV vaccine is permitted (that is, it meets the requirements of Islamic law) |
|
| Semiformal meetings and interpersonal contacts | Review of evidence and development of consensus on priority for and benefits of HPV immunisation |
| Reporting and management of adverse events after immunisation, including appropriate clinical care and accurate information to anticipate and prevent negative rumours | ||
|
| Road shows for non-governmental organisations and other concerned agencies and individuals | Platform to discuss concerns and provide convincing reassurance |
Table 3 Funds allocated for and expenditure of the programme on HPV immunisation*25
| Initial implementation (£) | Sustained implementation (£) | |||||
|---|---|---|---|---|---|---|
| Government allocation for HPV | Expenditure for HPV 2010-11 | Expenditure by procurement cycle† | ||||
| 2012-13 | 2014-16‡ | |||||
| Ministry of health | Pharmaceutical company | |||||
| Vaccine | 30m | 10.4m | 200 000 | 12.6m | 12.6m | |
| Communications | 2m | |||||
| Training | 400 000 | |||||
| Estimated cost per student | 28.27 | 18.73 | 13.94 | |||
Currency calculations are approximate figures based on the average exchange rate for 2010. MYR 5=£1.
Government allocation was merged with the national budget for the expanded programme on immunisation.
Malaysia changed from three dose to two dose schedule for 2015-16.